2025
Coronary artery bypass surgery improves restricted mean survival time in patients with ischemic cardiomyopathy
Reinhardt S, Huang H, Parise H, Ahmad T, Velazquez E, Faridi K. Coronary artery bypass surgery improves restricted mean survival time in patients with ischemic cardiomyopathy. American Heart Journal Plus Cardiology Research And Practice 2025, 54: 100538. PMID: 40485767, PMCID: PMC12142554, DOI: 10.1016/j.ahjo.2025.100538.Peer-Reviewed Original ResearchCoronary Artery Bypass GraftingAll-Cause MortalityIschemic cardiomyopathyMean survival timeMedical therapyRestricted mean survival timeClinical trialsEndpoint of all-cause mortalityInternational multicenter randomized clinical trialSurvival timeCoronary artery bypass surgeryOptimal medical therapyMulticenter Randomized Clinical TrialBenefit of coronary artery bypass graftingEffect of coronary artery bypass graftingIschemic heart failureArtery bypass surgeryCox proportional hazards modelsArtery Bypass GraftingRandomized clinical trialsProportional hazards modelSurgical treatmentBypass surgeryHeart failureBypass Grafting
2024
Recipient functional status impacts on short and long-term intestinal transplant outcomes in United States adults
Boateng S, Ameyaw P, Gyabaah S, Adjepong Y, Njei B. Recipient functional status impacts on short and long-term intestinal transplant outcomes in United States adults. World Journal Of Transplantation 2024, 14: 93561. PMID: 39295973, PMCID: PMC11317861, DOI: 10.5500/wjt.v14.i3.93561.Peer-Reviewed Original ResearchIntestinal transplant outcomesMedian survival timeTransplant outcomesSurvival outcomesFunctional statusUnited States adultsPost-transplant survival outcomesSurvival timeMultivariate Cox regressionPoor survival outcomesKaplan-Meier curvesKarnofsky performance statusFunctional impairmentHigher risk of mortalityRetrospective cohort studyPost-transplant outcomesSevere impairmentRisk of mortalityImpact post-transplant outcomesSevere functional impairmentMedian agePerformance statusPrognostic indicatorIntestinal transplantationKidney transplantationPredictive modeling of gene mutations for the survival outcomes of epithelial ovarian cancer patients
C. M, Lavi E, Altwerger G, Lin Z, Ratner E. Predictive modeling of gene mutations for the survival outcomes of epithelial ovarian cancer patients. PLOS ONE 2024, 19: e0305273. PMID: 38976671, PMCID: PMC11230535, DOI: 10.1371/journal.pone.0305273.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerEpithelial ovarian cancer patientsEpithelial ovarian cancer casesGene mutation signaturesPlatinum-based chemotherapyThe Cancer Genome AtlasResponse to treatmentOverall survivalGene mutationsMutational signaturesHomologous recombinationSurvival outcomesIncreased sensitivity to platinum-based chemotherapySensitivity to platinum-based chemotherapyAssociated with increased chemoresistanceResistance to platinum-based chemotherapySurvival timeSurvival rateFavorable response to treatmentPlatinum-induced DNA damageKaplan-Meier survival analysisPrediction of survival outcomesOvarian cancer patientsOverall survival ratePrediction of treatment outcomeClinicopathologic Characteristics of MYC Copy Number Amplification in Breast Cancer
Sun T, Golestani R, Zhan H, Krishnamurti U, Harigopal M, Zhong M, Liang Y. Clinicopathologic Characteristics of MYC Copy Number Amplification in Breast Cancer. International Journal Of Surgical Pathology 2024, 33: 59-64. PMID: 38839260, DOI: 10.1177/10668969241256109.Peer-Reviewed Original ResearchBreast cancerCopy number amplificationClinicopathological characteristicsAssociation with <i>TP53</i> mutation. InAssociated with invasive ductal carcinomaEstrogen receptor (ER)-negativeDisease-free survival timeGene copy number amplificationC-myc immunostainingNon-amplified tumorsTP53</i> mutationsTriple-negative statusMetastatic breast cancerInvasive ductal carcinomaMYC protein overexpressionBreast cancer patientsTriple-negativeDuctal carcinomaClinicopathological featuresGenetic abnormalitiesClinical dataImmunohistochemical studiesCancer patientsProtein overexpressionSurvival timeTreatment-wise glioblastoma survival Inference with multi-parametric preoperative MRI
Liu X, Shusharina N, Shih H, Kuo C, El Fakhri G, Woo J. Treatment-wise glioblastoma survival Inference with multi-parametric preoperative MRI. Proceedings Of SPIE--the International Society For Optical Engineering 2024, 12927: 129272h-129272h-5. PMID: 39444513, PMCID: PMC11497473, DOI: 10.1117/12.3006897.Peer-Reviewed Original Research
2023
Neutrophil-targeted combinatorial nanosystems for suppressing bacteremia-associated hyperinflammation and MRSA infection to improve survival rates
Chang Y, Lin C, Chen C, Hwang E, Alshetaili A, Yu H, Fang J. Neutrophil-targeted combinatorial nanosystems for suppressing bacteremia-associated hyperinflammation and MRSA infection to improve survival rates. Acta Biomaterialia 2023, 174: 331-344. PMID: 38061677, DOI: 10.1016/j.actbio.2023.11.040.Peer-Reviewed Original ResearchConceptsMethicillin-resistant Staphylococcus aureusMethicillin-resistant Staphylococcus aureus infectionIntracellular bacterial countsMouse bacteremia modelBacteremia modelSurvival rateEffective treatmentInhibition of cytokine releaseMedian survival timeDecreased neutrophil activationImproved survival ratesOrgan distributionIncreased survival rateMRSA coloniesAntibody-conjugated nanoparticlesMRSA burdenOrgan dysfunctionCytokine releaseLy6GCytokine/chemokine releaseProlonged circulationPeripheral organsTargeted nanoparticlesFree drugSurvival timeFrailty and long-term survival among patients in Australian intensive care units with metastatic cancer (FRAIL-CANCER study): a retrospective registry-based cohort study
Alamgeer M, Ling R, Ueno R, Sundararajan K, Sundar R, Pilcher D, Subramaniam A. Frailty and long-term survival among patients in Australian intensive care units with metastatic cancer (FRAIL-CANCER study): a retrospective registry-based cohort study. The Lancet Healthy Longevity 2023, 4: e675-e684. PMID: 38042160, DOI: 10.1016/s2666-7568(23)00209-x.Peer-Reviewed Original ResearchConceptsIntensive care unitRegistry-based cohort studyLong-term survivalAustralian intensive care unitsRetrospective registry-based cohort studyMetastatic cancerAssociated with shorter survival timeEffect of frailtyClinical Frailty ScaleShorter survival timeSurvival timeCohort studyAssociated with poor long-term survivalCare unitPoor long-term survivalIntensive care unit admissionTime-limited trialsCandidacy of patientsCox proportional hazards regression modelsRobust sandwich variance estimatorProportion of patientsProportional hazards regression modelsHazards regression modelsImpact of frailtyOverall survivalEPID-28. YEARS OF LIFE LOST FOR BRAIN AND OTHER CENTRAL NERVOUS SYSTEM TUMORS IN THE UNITED STATES, 2018
Neff C, Price M, Gerstl J, Kruchko C, Barnholtz-Sloan J, Bernstock J, Smith T, Claus E, Ostrom Q. EPID-28. YEARS OF LIFE LOST FOR BRAIN AND OTHER CENTRAL NERVOUS SYSTEM TUMORS IN THE UNITED STATES, 2018. Neuro-Oncology 2023, 25: v121-v121. PMCID: PMC10639734, DOI: 10.1093/neuonc/noad179.0460.Peer-Reviewed Original ResearchCentral nervous system tumorsNervous system tumorsTotal YLLYears of lifeSystem tumorsAtypical teratoid/rhabdoid tumorCancer-specific mortalityShorter survival timeNon-malignant tumorsCDC's National ProgramNational Vital Statistics SystemRace/ethnicityAge of deathNational burdenCancer morbidityVital Statistics SystemSpecific histopathologyRhabdoid tumorSurvival timeLife LostPremature deathTumorsYLLNational programMortality dataBevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman H, Prados M, Wen P, Mikkelsen T, Schiff D, Abrey L, Yung W, Paleologos N, Nicholas M, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T. Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma. Journal Of Clinical Oncology 2023, 41: 4945-4952. PMID: 37935104, DOI: 10.1200/jco.22.02772.Peer-Reviewed Original ResearchBevacizumab alone groupObjective response rateIrinotecan groupRecurrent glioblastomaResponse rateMedian overall survival timeProgression-free survival ratesEnd pointEfficacy of bevacizumabIndependent radiology reviewPrimary end pointSecondary end pointsProgression-free survivalOverall survival timeExperienced gradeNoncomparative trialsOverall survivalPatients patientsAdverse eventsRadiology reviewIntracranial hemorrhageBevacizumabSurvival timePatientsIrinotecanHistology Shift in Esophageal Cancer Between Biopsies and Resections After Neoadjuvant Therapy: A Pilot Study
Hou T, Yang Z, Zhang Q, Zhang X, Liao X, Lin J. Histology Shift in Esophageal Cancer Between Biopsies and Resections After Neoadjuvant Therapy: A Pilot Study. International Journal Of Surgical Pathology 2023, 32: 920-925. PMID: 37899731, DOI: 10.1177/10668969231208029.Peer-Reviewed Original ResearchNeoadjuvant therapyEsophageal adenocarcinomaNeuroendocrine neoplasmsNeuroendocrine carcinomaSurvival rateOverall median survival timeEsophageal neuroendocrine carcinomaPreoperative neoadjuvant therapyAdvanced esophageal adenocarcinomaMedian survival timeObserved survival ratesMainstay treatmentResidual adenocarcinomaConventional adenocarcinomaEsophageal cancerNeuroendocrine morphologyFocal positivitySurvival timeNeuroendocrine componentAdenocarcinomaBiopsyResectionSmall seriesPatientsNeoplasmsGilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML
Pratz K, Cherry M, Altman J, Cooper B, Podoltsev N, Cruz J, Lin T, Schiller G, Jurcic J, Asch A, Wu R, Hill J, Gill S, James A, Rich E, Hasabou N, Perl A, Levis M. Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML. Journal Of Clinical Oncology 2023, 41: 4236-4246. PMID: 37379495, DOI: 10.1200/jco.22.02721.Peer-Reviewed Original ResearchConceptsPhase Ib studyMaintenance therapyConsolidation chemotherapyDose escalationFLT3 inhibitorsIb studyHigh-dose cytarabine consolidationMedian overall survival timeSingle-agent maintenance therapyComplete response rateHigher trough levelsOverall survival timeCytarabine consolidationChemotherapy regimenDose expansionAdult patientsIntensive inductionTrough levelsCount recoveryMedian timeRandomized trialsInduction cyclesSurvival timeDay 1Response rateAssessment of Regional Nursing Home Preparedness for and Regulatory Responsiveness to Wildfire Risk in the Western US
Festa N, Throgmorton K, Davis-Plourde K, Dosa D, Chen K, Zang E, Kelly J, Gill T. Assessment of Regional Nursing Home Preparedness for and Regulatory Responsiveness to Wildfire Risk in the Western US. JAMA Network Open 2023, 6: e2320207. PMID: 37358851, PMCID: PMC10293909, DOI: 10.1001/jamanetworkopen.2023.20207.Peer-Reviewed Original ResearchConceptsCross-sectional studyNursing homesNursing home characteristicsMean survival timeUS nursing homesGreater mean numberPrimary outcomeUS CentersExposure statusMAIN OUTCOMEElevated riskSurvival timeSurvival analysisPresence of deficienciesMore deficienciesRisk statusEmergency preparednessHome characteristicsMean numberRiskPreparedness standardsDeficiencyResponsivenessHigh percentageOutcomes
2022
Population-Based Estimates of 1-Year Mortality After Major Surgery Among Community-Living Older US Adults
Gill TM, Vander Wyk B, Leo-Summers L, Murphy TE, Becher RD. Population-Based Estimates of 1-Year Mortality After Major Surgery Among Community-Living Older US Adults. JAMA Surgery 2022, 157: e225155. PMID: 36260323, PMCID: PMC9582971, DOI: 10.1001/jamasurg.2022.5155.Peer-Reviewed Original ResearchConceptsPopulation-based estimatesMajor surgeryMean survival timeOlder US adultsProbable dementiaUS adultsSurvival timeSex-adjusted hazard ratioProspective longitudinal cohort studyCommunity-living older adultsLongitudinal cohort studyPotential prognostic valueService Medicare beneficiariesNon-Hispanic blacksNon-Hispanic whitesAging Trends StudyGeriatric characteristicsCohort studyGeriatric surgeryHazard ratioNonelective surgeryElective surgeryGeriatric conditionsPrognostic valueMean ageQuantitative Echocardiographic Assessment and Optimal Criteria for Early Intervention in Asymptomatic Tricuspid Regurgitation
Akintoye E, Wang T, Nakhla M, Ali A, Fava A, Akyuz K, Popovic Z, Pettersson G, Gillinov A, Xu B, Griffin B, Desai M. Quantitative Echocardiographic Assessment and Optimal Criteria for Early Intervention in Asymptomatic Tricuspid Regurgitation. JACC Cardiovascular Imaging 2022, 16: 13-24. PMID: 36274042, DOI: 10.1016/j.jcmg.2022.08.004.Peer-Reviewed Original ResearchConceptsTricuspid regurgitationMedian survival timeRisk factorsAsymptomatic patientsEchocardiographic parametersSurvival timeEarly interventionOptimal timingRight heart parametersSymptomatic tricuspid regurgitationSignificant tricuspid regurgitationFree wall strainHigh operative mortalitySex-matched cohortQuantitative echocardiographic assessmentKey prognostic markersCause mortalityOperative mortalityTR patientsEchocardiographic assessmentLate presentationPoor outcomePrognostic utilityPrognostic valuePrognostic markerOral Health and Mortality Among Older Adults: A Doubly Robust Survival Analysis
Yu J, Qin W, Huang W, Thomas K. Oral Health and Mortality Among Older Adults: A Doubly Robust Survival Analysis. American Journal Of Preventive Medicine 2022, 64: 9-16. PMID: 36150950, PMCID: PMC11018359, DOI: 10.1016/j.amepre.2022.08.006.Peer-Reviewed Original ResearchConceptsSelf-rated oral healthCommunity-dwelling older adultsOral healthOlder adultsSurvival timeBetter self-rated oral healthNational Death Index mortality dataProportional hazards regression modelsInverse probabilityObjective clinical indicatorsOral health measuresSubjective oral healthHazards regression modelsNutrition Examination SurveyThird National HealthSurvival estimationCause mortalityPeriodontal conditionsDental screeningDental cariesExamination SurveyClinical indicatorsRisk factorsNational HealthCox modelEvaluating information loss in the National Cancer Database from cases lost to follow‐up
Cotler JH, Nogueira L, McCabe R, Nelson H, Brajcich BC, Boffa DJ, Lum SS, Harris JB, Hawhee V, Mullett TW, Bilimoria KY, Palis BE. Evaluating information loss in the National Cancer Database from cases lost to follow‐up. Journal Of Surgical Oncology 2022, 126: 1123-1132. PMID: 36029288, DOI: 10.1002/jso.26977.Peer-Reviewed Original ResearchConceptsNational Cancer DatabaseCancer casesPediatric casesAdult casesCancer DatabaseRectal cancer casesLung cancer casesMean survival timeBreast cancer casesHazard ratioCancer RegistryYears postdiagnosisSurvival outcomesLymphoma casesSurvival timeLeukemia casesSurvival analysisResource burdenFollowTotalMinimal differencesYearsAnnual increasePostdiagnosisPatientsIncidence and Trends in the Use of Palliative Care among Patients with Reduced, Middle-Range, and Preserved Ejection Fraction Heart Failure
Feder SL, Murphy TE, Abel EA, Akgün KM, Warraich HJ, Ersek M, Fried T, Redeker NS. Incidence and Trends in the Use of Palliative Care among Patients with Reduced, Middle-Range, and Preserved Ejection Fraction Heart Failure. Journal Of Palliative Medicine 2022, 25: 1774-1781. PMID: 35763838, PMCID: PMC9784595, DOI: 10.1089/jpm.2022.0093.Peer-Reviewed Original ResearchConceptsPalliative careEjection fractionHeart failureHF subtypesIncidence rateEjection fraction heart failureMid-range ejection fractionRetrospective cohort studyKaplan-Meier analysisClinical practice guidelinesCare of patientsMean survival timePalliative needsCohort studyHF diagnosisHFpEFHFmEFPractice guidelinesSurvival timePatientsSix weeksVeterans AffairsSubtypesHFrEFCareSoluble CD14-associated DNA methylation sites predict mortality among men with HIV infection
Titanji BK, Wang Z, Chen J, Hui Q, So-Armah K, Freiberg M, Justice AC, Ke X, Marconi VC, Sun YV. Soluble CD14-associated DNA methylation sites predict mortality among men with HIV infection. AIDS 2022, 36: 1563-1571. PMID: 35979830, PMCID: PMC9394925, DOI: 10.1097/qad.0000000000003279.Peer-Reviewed Original ResearchConceptsVeterans Aging Cohort StudyAging Cohort StudyElevated plasma levelsCox regression modelUnderstanding of prognosisPeripheral blood samplesPotential therapeutic targetEpigenome-wide association studiesMultiple testingCause mortalitySCD14 levelsCohort studyHIV infectionPlasma levelsSoluble CD14Disease progressionImmune functionSurvival timeBlood samplesSCD14Therapeutic targetPWHAntiviral responseSignificant associationDNAm sites
2021
S65 Genome-wide association study of survival times after diagnosis of idiopathic pulmonary fibrosis
Allen R, Oldham J, Lorenzo-Salazar J, Molyneaux P, Ma S, Stockwell A, Joseph C, Kim J, Guillen-Guio B, Hernandez-Beeftink T, Kropski J, Huang Y, Lee C, Adegunsoye A, Pugashetti J, Linderholm A, Vo V, Strek M, Hubbard R, Hirani N, Whyte M, Hart S, Nicholson A, Parfrey H, Rassl D, Wallace W, Fahy W, Valenzi E, Zhang Y, Kaminski N, Wolters P, Molina-Molina M, Martinez F, Hall I, Tobin, Maher T, Blackwell T, Yaspan B, Jenkins R, Flores C, Wain L, Noth I. S65 Genome-wide association study of survival times after diagnosis of idiopathic pulmonary fibrosis. Thorax 2021, 76: a43-a43. DOI: 10.1136/thorax-2021-btsabstracts.71.Peer-Reviewed Original ResearchGenome-wide analysisIdiopathic pulmonary fibrosisAssociation studiesGenome-wide association studiesGenetic variantsImportant biological processesWide association studyTwo-stage GWASIPF casesIPF survivalSurvival timeDisease progressionDNA regionsFirst GWASLikely genePulmonary fibrosisGene expressionBiological processesDiagnosis of IPFGenetic principal componentsProgression of IPFDisease riskStage 1Genetic determinantsCox proportional hazards modelThe association of neighborhood walkability with health outcomes in older adults after acute myocardial infarction: The SILVER-AMI study
Roy B, Hajduk AM, Tsang S, Geda M, Riley C, Krumholz HM, Chaudhry SI. The association of neighborhood walkability with health outcomes in older adults after acute myocardial infarction: The SILVER-AMI study. Preventive Medicine Reports 2021, 23: 101391. PMID: 34040930, PMCID: PMC8141908, DOI: 10.1016/j.pmedr.2021.101391.Peer-Reviewed Original ResearchAcute myocardial infarctionSILVER-AMI StudyPhysical activityMental healthMyocardial infarctionNeighborhood walkabilityOlder adultsHealth outcomesSocial supportCommunity-living adultsSecondary outcomesCoronary diseasePrimary outcomeSF-12Longitudinal cohortPhysical therapyAdjusted modelSurvival timeBetter outcomesGreater walkabilitySurvival analysisMobility limitationsPhysical healthOutcomesAdults
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply